It is very uncertain whether higher changes food allergy ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes all allergic disease ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).
Higher national income was strongly associated with lower odds of poor oral health (OR 0.10, 95% CI 0.03 to 0.37; about 90% lower odds); not GRADE-rated.
Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).
Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).
Higher‐dose may leads to higher treatment withdrawals ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
Higher‐dose showed no clear difference in treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
It is very uncertain whether higher dose changes deaths compared with lower dose (very low certainty).
It is very uncertain whether higher dose changes intermediate syndrome compared with lower dose (very low certainty).
It is very uncertain whether higher dose changes ventilated compared with lower dose (very low certainty).
It is very uncertain whether early and late (day 1 to 28 after birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).